Cargando…
RESOLVE-ing sepsis in children – not yet!
The Researching Severe Sepsis and Organ Dysfunction in Children: A Global Perspective study of drotrecogin alfa activated versus placebo was the largest study of adjunctive therapy ever performed in children with severe sepsis. Despite this, the study failed to show any significant differences in ou...
Autor principal: | |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2206411/ https://www.ncbi.nlm.nih.gov/pubmed/17561989 http://dx.doi.org/10.1186/cc5919 |
_version_ | 1782148465563795456 |
---|---|
author | Nadel, Simon |
author_facet | Nadel, Simon |
author_sort | Nadel, Simon |
collection | PubMed |
description | The Researching Severe Sepsis and Organ Dysfunction in Children: A Global Perspective study of drotrecogin alfa activated versus placebo was the largest study of adjunctive therapy ever performed in children with severe sepsis. Despite this, the study failed to show any significant differences in outcome between the treatment and placebo groups. The results raise questions about how we should perform meaningful clinical trials in relatively rare conditions such as paediatric sepsis, where the easily measurable endpoints (such as death) are infrequent. A radical rethink of the design of such studies is urgently needed. |
format | Text |
id | pubmed-2206411 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-22064112008-01-19 RESOLVE-ing sepsis in children – not yet! Nadel, Simon Crit Care Commentary The Researching Severe Sepsis and Organ Dysfunction in Children: A Global Perspective study of drotrecogin alfa activated versus placebo was the largest study of adjunctive therapy ever performed in children with severe sepsis. Despite this, the study failed to show any significant differences in outcome between the treatment and placebo groups. The results raise questions about how we should perform meaningful clinical trials in relatively rare conditions such as paediatric sepsis, where the easily measurable endpoints (such as death) are infrequent. A radical rethink of the design of such studies is urgently needed. BioMed Central 2007 2007-06-08 /pmc/articles/PMC2206411/ /pubmed/17561989 http://dx.doi.org/10.1186/cc5919 Text en Copyright © 2007 BioMed Central Ltd |
spellingShingle | Commentary Nadel, Simon RESOLVE-ing sepsis in children – not yet! |
title | RESOLVE-ing sepsis in children – not yet! |
title_full | RESOLVE-ing sepsis in children – not yet! |
title_fullStr | RESOLVE-ing sepsis in children – not yet! |
title_full_unstemmed | RESOLVE-ing sepsis in children – not yet! |
title_short | RESOLVE-ing sepsis in children – not yet! |
title_sort | resolve-ing sepsis in children – not yet! |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2206411/ https://www.ncbi.nlm.nih.gov/pubmed/17561989 http://dx.doi.org/10.1186/cc5919 |
work_keys_str_mv | AT nadelsimon resolveingsepsisinchildrennotyet |